Wall Street analysts predict that TherapeuticsMD, Inc. (NASDAQ:TXMD) will post earnings per share of ($0.10) for the current quarter, Zacks reports. Three analysts have made estimates for TherapeuticsMD’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.11). TherapeuticsMD reported earnings per share of ($0.19) in the same quarter last year, which indicates a positive year-over-year growth rate of 47.4%. The company is expected to issue its next earnings report on Thursday, February 18th.
According to Zacks, analysts expect that TherapeuticsMD will report full year earnings of ($0.62) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.57). For the next financial year, analysts forecast that the firm will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.54) to ($0.21). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for TherapeuticsMD.
A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of TherapeuticsMD in a research note on Tuesday, November 10th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Friday, November 13th. Finally, HC Wainwright dropped their target price on shares of TherapeuticsMD from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, January 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $6.29.
Shares of TXMD stock traded down $0.12 during mid-day trading on Tuesday, reaching $1.58. The company’s stock had a trading volume of 409,752 shares, compared to its average volume of 15,857,688. TherapeuticsMD has a 1-year low of $0.85 and a 1-year high of $2.75. The company has a market cap of $472.13 million, a P/E ratio of -2.25 and a beta of 2.19. The firm’s 50-day moving average is $1.64 and its two-hundred day moving average is $1.46.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
See Also: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.